AU2014342004B2 - Modular particles for immunotherapy - Google Patents

Modular particles for immunotherapy Download PDF

Info

Publication number
AU2014342004B2
AU2014342004B2 AU2014342004A AU2014342004A AU2014342004B2 AU 2014342004 B2 AU2014342004 B2 AU 2014342004B2 AU 2014342004 A AU2014342004 A AU 2014342004A AU 2014342004 A AU2014342004 A AU 2014342004A AU 2014342004 B2 AU2014342004 B2 AU 2014342004B2
Authority
AU
Australia
Prior art keywords
cells
tumor
nanoparticles
cell
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014342004A
Other languages
English (en)
Other versions
AU2014342004A1 (en
Inventor
Tarek Fahmy
Brian Horsburgh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2014342004A1 publication Critical patent/AU2014342004A1/en
Application granted granted Critical
Publication of AU2014342004B2 publication Critical patent/AU2014342004B2/en
Priority to AU2017272274A priority Critical patent/AU2017272274A1/en
Priority to AU2019246802A priority patent/AU2019246802B2/en
Priority to AU2021221886A priority patent/AU2021221886A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2014342004A 2013-11-01 2014-10-31 Modular particles for immunotherapy Active AU2014342004B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017272274A AU2017272274A1 (en) 2013-11-01 2017-12-07 Modular particles for immunotherapy
AU2019246802A AU2019246802B2 (en) 2013-11-01 2019-10-09 Modular particles for immunotherapy
AU2021221886A AU2021221886A1 (en) 2013-11-01 2021-08-26 Modular particles for immunotherapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361899080P 2013-11-01 2013-11-01
US61/899,080 2013-11-01
US201462040242P 2014-08-21 2014-08-21
US62/040,242 2014-08-21
PCT/US2014/063545 WO2015066535A1 (en) 2013-11-01 2014-10-31 Modular particles for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017272274A Division AU2017272274A1 (en) 2013-11-01 2017-12-07 Modular particles for immunotherapy

Publications (2)

Publication Number Publication Date
AU2014342004A1 AU2014342004A1 (en) 2016-05-26
AU2014342004B2 true AU2014342004B2 (en) 2017-10-26

Family

ID=51999513

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014342004A Active AU2014342004B2 (en) 2013-11-01 2014-10-31 Modular particles for immunotherapy
AU2017272274A Abandoned AU2017272274A1 (en) 2013-11-01 2017-12-07 Modular particles for immunotherapy
AU2019246802A Active AU2019246802B2 (en) 2013-11-01 2019-10-09 Modular particles for immunotherapy
AU2021221886A Abandoned AU2021221886A1 (en) 2013-11-01 2021-08-26 Modular particles for immunotherapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017272274A Abandoned AU2017272274A1 (en) 2013-11-01 2017-12-07 Modular particles for immunotherapy
AU2019246802A Active AU2019246802B2 (en) 2013-11-01 2019-10-09 Modular particles for immunotherapy
AU2021221886A Abandoned AU2021221886A1 (en) 2013-11-01 2021-08-26 Modular particles for immunotherapy

Country Status (11)

Country Link
US (3) US9884026B2 (https=)
EP (1) EP3062779B1 (https=)
JP (4) JP6845691B2 (https=)
KR (2) KR102460800B1 (https=)
CN (2) CN105848649B (https=)
AU (4) AU2014342004B2 (https=)
CA (2) CA2929277C (https=)
ES (1) ES2982087T3 (https=)
RU (1) RU2672055C2 (https=)
WO (1) WO2015066535A1 (https=)
ZA (1) ZA201602826B (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2347775T (pt) 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9603800B2 (en) 2012-04-12 2017-03-28 Yale University Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자
WO2015108912A1 (en) 2014-01-16 2015-07-23 MUSC Foundation for Research and Development Targeted nanocarriers for the administration of immunosuppressive agents
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
EP3270932B1 (en) 2015-03-16 2024-08-21 PDX Pharmaceuticals, Inc. Cross-linked polymer modified nanoparticles
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US10493030B2 (en) 2015-05-22 2019-12-03 Aphios Corporation Combination HIV therapeutic
IL293655B2 (en) * 2015-05-27 2025-04-01 Univ Northwestern Modified carbohydrate particles and particulate compositions for modulating immune response
CN120392779A (zh) 2015-06-15 2025-08-01 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017144548A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and doxorubicin-loaded poly(cyanoacrylate) nanoparticles
KR102413032B1 (ko) 2016-03-01 2022-06-24 노쓰 캐롤라이나 스테이트 유니버시티 마이크로니들 패치-보조된 전달에 의한 향상된 암 면역요법
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CA3056802A1 (en) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Non-viral, non-cationic nanoparticles and uses thereof
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
GB201804634D0 (en) * 2018-03-22 2018-05-09 Aqdot Ltd Emulsion stabiliser
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2019217552A1 (en) * 2018-05-09 2019-11-14 Yale University Particles for spatiotemporal release of agents
US20210275588A1 (en) * 2018-07-10 2021-09-09 The Regents Of The University Of California Biomolecule Coated Particles and Films and Uses Thereof
WO2020014644A1 (en) * 2018-07-12 2020-01-16 The Regents Of The University Of Michigan Compositions and methods for metal containing formulations capable of modulating immune response
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3853258A4 (en) * 2018-09-20 2022-11-16 Arizona Board of Regents on behalf of the University of Arizona TARGETED PART-DRUG-GRAFTED IMMUNE CELLS AND METHODS OF USE
EP4635486A3 (en) * 2018-10-01 2025-12-24 The Board of Trustees of the Leland Stanford Junior University Injectable hydrogels for controlled release of immunomodulatory compounds
EP3866832B1 (en) * 2018-10-19 2024-12-11 University of Rochester Immunomodulatory cytokines in combination with radiation treatment for unresectable pancreatic cancer
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
WO2020136657A1 (en) 2018-12-28 2020-07-02 Ramot At Tel-Aviv University Ltd. Polymeric nanovaccines and uses thereof
WO2020150623A1 (en) * 2019-01-18 2020-07-23 University Of Georgia Research Foundation, Inc. Salt nanoparticles and compositions and methods of use thereof
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
WO2021011501A1 (en) 2019-07-12 2021-01-21 Oregon Health & Science University Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
EP4031582A4 (en) * 2019-09-18 2023-10-04 The Regents of the University of California IMMUNOACTIVE MICROPARTICLES AND ASSOCIATED USES
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
RU2712212C1 (ru) * 2019-10-28 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
CA3160922A1 (en) 2019-12-05 2021-06-10 Brock A. LINDSEY Protein-loaded plga nanospheres
WO2021137611A1 (ko) * 2019-12-30 2021-07-08 (주)테라베스트 나노 구조체가 부착된 면역세포
US20230093708A1 (en) * 2020-03-04 2023-03-23 Duke University Protein nanoparticle design and application
EP4149550A4 (en) * 2020-05-15 2024-07-03 The Board of Trustees of the Leland Stanford Junior University TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF
EP4175618A4 (en) * 2020-07-01 2024-08-07 Cello Therapeutics, Inc. Platelet membrane coated nanoparticles and uses thereof
CN112451504B (zh) * 2020-11-09 2022-10-18 四川大学华西医院 一种载EBV-LMP2 mRNA的核-壳纳米粒的制备方法及应用
US11672875B2 (en) 2021-03-17 2023-06-13 Saint Louis University Nanoparticle-alginate gels for X-ray imaging of the vasculature
WO2022225737A1 (en) * 2021-04-20 2022-10-27 Purdue Research Foundation Immunofunctional carrier, methods of uses, and composition matters as an antitumor immunotherapy
GB2629999B (en) * 2021-04-21 2025-03-26 Act Therapeutics Ltd Enhancement of treatment with immunotherapeutic agents
WO2022225203A1 (ko) * 2021-04-23 2022-10-27 서울대학교산학협력단 대식세포의 활성 조절용 조성물
WO2023113550A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 수지상세포 모방 기능성 나노구조체 및 이의 제조방법
WO2023113545A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
NO20221187A1 (en) 2022-11-04 2024-05-06 Exact Therapeutics As Method and system for calculating a point estimate of an ultrasound dose
WO2024128868A1 (ko) * 2022-12-15 2024-06-20 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
CN116172980A (zh) * 2022-12-28 2023-05-30 上海百心安生物技术股份有限公司 一种核壳结构胶束微球及其制备方法和应用
CN118576717A (zh) * 2023-03-01 2024-09-03 清华大学 生物分子递送载体及其制备和应用
CN117731637A (zh) * 2023-12-20 2024-03-22 上海爱莫思生物技术有限公司 一种mdp纳米颗粒及其应用
WO2025149619A1 (en) * 2024-01-12 2025-07-17 Topas Therapeutics Gmbh Nanoparticles comprising amphiphilic polymers and lipids for the targeted delivery of antigens
CN120324344B (zh) * 2025-04-18 2025-10-17 广州医科大学附属第一医院横琴医院(横琴粤澳深度合作区中心医院) 一种肿瘤微环境响应型级联靶向小激活核酸纳米药物的制备方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5354867A (en) 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1995015746A1 (en) 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EP3263581B2 (en) * 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101355965A (zh) 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
US20070014845A1 (en) 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007056539A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US20080267455A1 (en) 2005-12-20 2008-10-30 Koninklijke Philips Electronics N. V. Method for Movement Compensation of Image Data
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
BRPI0810899A2 (pt) * 2007-04-13 2014-10-29 Univ North Texas Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009020094A1 (ja) 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited 疎水性分子で修飾した抗体
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US9283184B2 (en) * 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
US20120021036A1 (en) 2009-01-15 2012-01-26 The Regents Of The University Of California Composite nanostructures and methods for making and using them
CN102596178B (zh) 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293690A1 (en) 2010-05-27 2011-12-01 Tyco Healthcare Group Lp Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
RU2013127625A (ru) * 2010-11-18 2014-12-27 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
KR20140041522A (ko) * 2011-05-09 2014-04-04 인스티튜트 퀴믹 데 사리아 약물 전달용 중합체 나노입자
US9603800B2 (en) * 2012-04-12 2017-03-28 Yale University Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EGILMEZ, N.K. et al., ‘Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model’, Cancer Immunology, Immunotherapy. 1998, Vol. 46, pages 21-24 *

Also Published As

Publication number Publication date
CN110302162A (zh) 2019-10-08
JP6845691B2 (ja) 2021-03-24
CN105848649A (zh) 2016-08-10
AU2019246802A1 (en) 2019-10-31
JP2020075940A (ja) 2020-05-21
CA2929277C (en) 2018-01-16
US20160303052A1 (en) 2016-10-20
AU2017272274A1 (en) 2018-01-04
KR102460800B1 (ko) 2022-10-31
CA2987519A1 (en) 2015-05-07
EP3062779A1 (en) 2016-09-07
AU2021221886A1 (en) 2021-09-23
US20180200196A1 (en) 2018-07-19
ES2982087T3 (es) 2024-10-14
JP2022078345A (ja) 2022-05-24
ZA201602826B (en) 2019-10-30
CN105848649B (zh) 2019-08-02
CA2929277A1 (en) 2015-05-07
BR112016009643A8 (pt) 2021-02-23
EP3062779B1 (en) 2024-06-12
RU2016121422A (ru) 2017-12-04
WO2015066535A1 (en) 2015-05-07
AU2014342004A1 (en) 2016-05-26
US10751291B2 (en) 2020-08-25
EP3062779C0 (en) 2024-06-12
US9884026B2 (en) 2018-02-06
BR112016009643A2 (pt) 2017-12-05
JP6929572B2 (ja) 2021-09-01
US20210015758A1 (en) 2021-01-21
AU2019246802B2 (en) 2021-05-27
JP2020073617A (ja) 2020-05-14
KR20160085794A (ko) 2016-07-18
RU2672055C2 (ru) 2018-11-09
JP2016536312A (ja) 2016-11-24
KR20190126452A (ko) 2019-11-11

Similar Documents

Publication Publication Date Title
AU2019246802B2 (en) Modular particles for immunotherapy
US12156939B2 (en) Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
BR112016009643B1 (pt) Composição nanoparticulada

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTOR HORSBURGH, BRIAN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE SUPPLEMENT TO THE OFFICIAL JOURNAL DATED 18 JAN 2018

FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: MODULATE THERAPEUTICS INC.